Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira

Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.

Coherus BioSciences Inc. is betting big on biosimilars, and is one of an elite group of pure play biosimilar specialists looking to compete against significantly bigger players. Though Coherus is a relatively little-known newcomer, it is one of just seven drug companies to have submitted a biosimilar application to FDA, along with marquee names like Sandoz Inc., Amgen Inc. and Pfizer Inc. – and it has the chance to be first to market in some lucrative categories.

The Redwood City, Calif.-based upstart could be the first to launch a biosimilar version of Amgen's blockbuster Neulasta (pegfilgrastim). Coherus...

More from Business

More from Scrip